Novo Nordisk and United Laboratories report nearly 20% weight loss in a mid-stage trial of a next-gen triple-agonist therapy.
Nineteen point seven percent. A number that stops you mid-scroll. That was the average weight loss recorded after just 24 weeks among participants receiving the highest dose of UBT251, a new obesity drug jointly developed by Novo Nordisk and United Laboratories International. In a field already crowded with eye-catching statistics, the figure still lands with force, especially when you consider the time frame.
This was a mid-stage clinical trial conducted in China, comparing once-weekly injections of UBT251 with a placebo in people living with overweight or obesity. While those on placebo lost about 2% of their body weight, those on UBT251 lost close to a fifth. For many participants, that meant shedding more than 17 kilograms in under six months [1].
The question is no longer whether obesity drugs work; it is how far they can go and what kind of aging future they might help create.
UBT251 belongs to a newer category of treatments known as triple agonists, sometimes referred to as “triple G” drugs. Most current blockbuster obesity medications work by amplifying a single hormone signal that helps people feel full sooner. UBT251, by contrast, works on three hormonal pathways simultaneously, influencing appetite, blood sugar control and energy use.
Earlier drugs are like adjusting one thermostat in a large house. Triple agonists aim to fine-tune the heating, cooling and ventilation together. Less brute force, more system-level control. That systems approach helps explain why companies like Novo Nordisk are betting heavily on this class, even as their existing drugs (such as Wegovy) continue to dominate global sales.
The Chinese phase 2 trial enrolled 205 participants, all of whom had obesity or overweight with at least one related health condition. Alongside weight loss, UBT251 also improved waist circumference, blood glucose, blood pressure and blood lipids.
Obesity is rarely the disease that ends lives; it is the metabolic fallout that follows. Improvements across multiple risk factors hint at extending the healthspan that longevity researchers care deeply about. In other words, the promise here is not simply fewer kilograms, but fewer years spent managing chronic disease.
As with other drugs in this category, the most common side effects were gastrointestinal. According to the companies, most were mild to moderate and tended to fade over time, consistent with what doctors already see in incretin-based therapies.
Consistency is both reassuring and limiting. While the results are impressive, UBT251 is not a miracle cure, and it has not yet been proven for long-term use. The trial lasted 24 weeks, not decades. And real-world adherence, pricing and access will ultimately shape its impact as much as clinical data.
Still, Novo’s chief scientific officer, Martin Holst Lange, said the company was “very encouraged” by the results, pointing to both the magnitude of weight loss and the drug’s tolerability.
The announcement comes as competition in obesity therapeutics intensifies. Novo recently disclosed data showing its CagriSema drug achieved a 23% reduction in body weight over a longer study period, while Eli Lilly’s leading candidate has reported even higher figures in head-to-head trials.
Against that backdrop, UBT251’s appeal lies in its speed and efficiency. Nearly 20% weight loss in six months raises the possibility that future treatments could deliver meaningful metabolic resets earlier in life, potentially before decades of damage accumulate.
Novo has already initiated a global trial of UBT251 involving around 330 participants, with results expected in 2027, and plans to begin testing the drug in people with type 2 diabetes in 2026.
Obesity drugs like UBT251 may become foundational tools that make other longevity strategies – from cardiovascular prevention to cognitive health – more effective. UBT251 is still early in its journey, and much can change between phase 2 success and real-world impact. But obesity medicine is evolving quickly, and its intersection with longevity science is becoming impossible to ignore.
